Personalized Drug Selection for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

Overseen ByRobert C. Grant, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University Health Network, Toronto

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.

Eligibility Criteria

This trial is for individuals with pancreatic cancer. It's exploring if using Patient Derived Organoids (PDO) to select a personalized drug treatment can be effective. Participants must have a type of pancreatic cancer that qualifies and should meet other specific health criteria not detailed here.

Inclusion Criteria

I am able to get out of my bed or chair and move around.

I am 18 years old or older.

My cancer is a type of advanced pancreatic cancer that cannot be removed by surgery.

Exclusion Criteria

My heart's pumping ability is below 40%.

I do not have severe numbness or pain in my hands or feet.

I have had a serious stomach or intestinal bleed in the last month.

I received my last chemotherapy dose less than 3 weeks ago.

I have side effects from cancer treatment that are not severe, except for nerve pain.

I have serious heart problems like uncontrolled chest pain or heart failure.

Participant Groups

The study tests the effectiveness of various drugs (Colchicine, Selinexor, Abemaciclib, Ponatinib, Cobimetinib, Brigatinib, Neratinib, Doxorubicin, Etoposide, Ceritinib) chosen based on PDO models for treating pancreatic cancer. The main focus is on how many patients respond positively to their tailored treatment.

2Treatment groups

Experimental Treatment

Group I: Cohort BExperimental Treatment10 Interventions

Patients in this cohort will be entering the study for maintenance therapy with stable disease.

Group II: Cohort AExperimental Treatment10 Interventions

Patients in this cohort will be entering the study for treatment for progressive disease.